ARTEMISMED Artemis Medicare Services Q2 FY26 results (Jul–Sep 2025) and concall
Artemis Medicare reported strong financial performance for Q2 and H1 FY26, driven by robust revenue growth and improved EBITDA margins. The company highlighted strategic capacity expansions, including new operation theatres and upcoming facilities in Raipur and South Delhi, alongside advancements in technology and clinical offerings. Management expressed confidence in sustaining volume growth, improving ARPOB, and achieving mid-20s EBITDA margins with increased scale.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 14.1%, net profit up 36.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 241 | 232 | 240 | 255 | 275 +14% |
| EBITDA | 42 | 37 | 36 | 41 | 51 +21% |
| Net profit | 22 | 21 | 23 | 21 | 30 +36% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
